# Evaluate the Effect of Vimseltinib on P-glycoprotein (P-gp) Inhibition in Healthy Male Participants

> **NCT07744802** · PHASE1 · RECRUITING · sponsor: **Deciphera Pharmaceuticals, LLC** · enrollment: 20 (estimated)

## Conditions studied

- Healthy Male Participants

## Interventions

- **DRUG:** Vimseltinib
- **DRUG:** Dabigatran

## Key facts

- **NCT ID:** NCT07744802
- **Lead sponsor:** Deciphera Pharmaceuticals, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-09
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07744802

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07744802, "Evaluate the Effect of Vimseltinib on P-glycoprotein (P-gp) Inhibition in Healthy Male Participants". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07744802. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*